AbbVie (ABBV) announced that a new 6-month 45mg Lupron Depot strength has received Health Canada approval for the treatment of advanced prostate cancer. Lupron Depot is now available in four dosing options: 7.5 mg (1-Month), 22.5 mg (3-Month), 30 mg (4-Month), and 45 mg (6-Month). Lupron Depot was initially approved by Health Canada for advanced prostate cancer in 1989, providing 36 years of proven clinical use in Canada.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: